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Dr Brendan Stiles (New York, NY). Farshad, that was nicely
presented. It is a good continuation of the work your group has
done. I am a bit curious why you didn’t use a sham experiment
on the knockout mice. Or did you do that?
Dr Anvari. Our preliminary studies on these knockout mice
showed that they are comparable to our WT mice in terms of pul-
monary function, and we saw similar measurements as the WT
mice. So we did not include 2 sham groups in these experiments.
Dr Stiles. So the baseline levels of cytokine expression, things
like that, are no different between the knockout and the sham?
Dr Anvari. The baseline levels were similar for function. As far
as cytokines, previous studies have shown that the baseline levels
of some of the cytokines, including TNF-a and IL-6 are elevated
in the knockout mice. So we did not repeat those experiments.
Dr Stiles. I am just concerned that you are knocking out a proin-
flammatory gene and then you are showing that there is a decrease
in cytokine induction after IR, which you attribute to the treatment.
Some of those things are downstream of the proinflammatory path-
way that has been knocked out. I am concerned that what you are
showing is more just a function of knocking that out rather than ac-
tual protection from IR. Do you think there is a way to tease that
out?The Journal of Thoracic and CaDr Anvari. This is an interesting question. The limitation with
knockouts, as you mentioned, is that the observed effects may be
the result of the creation of the knockout itself. We do know that
the expression of other adenosine receptors are unchanged in these
knockouts. I would look at this as a first step. We recently acquired
agonists and antagonists for this receptor, and I think that will be the
next step to validate these results. Our preliminary results look
promising.
Dr Stiles. That is great. What is the delivery method of those, the
agonists and antagonists?
Dr Anvari. Intravenous injections via the external jugular.
Dr Frank Sellke (Providence, RI). I have a technical question.
You used a t test for your statistical analysis, yet you had multiple
groups. Shouldn’t you use a multiple comparison test rather than a t
test?
Dr Anvari. We performed an analysis of variance (ANOVA)
followed by a t test for unpaired data.
Dr Sellke.Yes, but if you havemultiple groups, you have to take
the multiple comparisons into consideration, not just an ANOVA.
You have to do a post hoc analysis with multiple comparisons like
a Bonferroni correction or one of these tests into play.
Dr Anvari. Correct. We did an ANOVA in conjunction with
a Tukey’s test. We also performed additional analyses by looking
at specific groups comparing 2 at a time using a t test.
Dr Sellke. So you are not really doing a Bonferroni correction if
you are doing just a t test.
Dr Anvari. No. ANOVA in conjunction with Tukey’s test. The
t test was used for additional analysis.
Dr Michael Jessen (Dallas, Tex). I enjoyed your study a lot.
That is good work. The biggest area in cardiothoracic surgery I
think where we see IR injury, as you pointed out, is in lung trans-
plantation, but it is a tough thing to model. In some ways your
model deviates from it. There is no denervation, no hypothermia,
no preservation solution, and no immunosuppression on board.
How confident are you that your findingswill bemaintained in a set-
ting that is more clinically relevant to lung transplantation?
Dr Anvari. Those are all very relevant issues. We adopted this
model as a first step in the process of better understanding the role
of this receptor in pulmonary IR. We chose a mouse model because
we had the benefit of the knockouts, and this provides a foundation.
We need to continue this work by using drugs in this model, and if
that confirms the results we are seeing, then we can take that to
a bigger animal and use a more clinically relevant model. But I
think this is an important first step in establishing that.
This in vivo model is, of course, as you mentioned, a warm is-
chemiamodel and doesn’t take into account all the factors youmen-
tioned, but in the mouse is the best model short of actual
transplantation, which has recently been done. But, as you can
imagine, it is technically challenging and not easily reproducible.
Dr Glen Van Arsdell (Toronto, Ontario, Canada). Your group
has been working with adenosine receptors for some time. The pro-
gram also does lung transplantation. Have you taken human tissue
to see whether there is a difference in expression and correlated that
with IR that you see clinically?
Dr Anvari. We have not used any human tissue in our experi-
ments so far.
Dr Van Arsdell. Is that coming down the line?
Dr Anvari. Hopefully, in the near future.rdiovascular Surgery c Volume 140, Number 4 877
